Dysregulated expression of repetitive DNA in ER+/HER2-breast cancer

被引:14
|
作者
Yandim, Cihangir [1 ,2 ]
Karakulah, Gokhan [2 ,3 ]
机构
[1] Izmir Univ Econ, Fac Engn, Dept Genet & Bioengn, TR-35330 Izmir, Turkey
[2] Dokuz Eylul Univ, Izmir Biomed & Genome Ctr IBG, Hlth Campus, TR-35340 Izmir, Turkey
[3] Dokuz Eylul Univ, Izmir Int Biomed & Genome Inst iBG Izmir, Hlth Campus, TR-35340 Izmir, Turkey
关键词
Breast cancer; Repetitive DNA; Survival; Transcriptome analysis; Bioinformatics; COMPREHENSIVE MOLECULAR PORTRAITS; TRANSPOSABLE ELEMENTS; GENE-EXPRESSION; ENDOGENOUS RETROVIRUSES; BREAST; HETEROCHROMATIN; TRANSCRIPTION; PROMOTERS; LANDSCAPE; DISEASES;
D O I
10.1016/j.cancergen.2019.09.002
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Limited studies on breast cancer indicated pathogenic changes in the expressions of some repeat elements. A global analysis was much needed within this context to distinguish the most significant repeats from more than a thousand repeat motifs. Utilising a previously presented RNA-seq dataset, we studied expression changes of all repeats in ER+/HER2- human breast tumour samples obtained from 22 patients in comparison to matched normal tissues. Fifty six (56) repeat subtypes including satellites and transposons were found to be differentially expressed and most of them were novel for breast cancer. HERVKC4-int and HERV1_LTRc, whose expressions correlated well with that of the estrogen receptor gene ESR1, were upregulated at the highest level. REP522 and D20S16 satellites were also significantly upregulated along with insignificant increases in the expressions of other satellites including HSATI and BSR/beta. Interestingly, expressions of REP522 and D20S16 correlated with many key breast cancer pathway (e.g. BRCA1, BRCA2, AKT1, MTOR, KRAS) and survival genes; possibly highlighting their importance in the carcinogenesis of breast. Additional differentially expressed elements such as L1P and various MER transposons also exhibited a similar pattern. Finally, our repeat enrichment analysis on the promoters of differentially expressed genes revealed further links between additional repeats and nearby genes. (C) 2019 Elsevier Inc. All rights reserved.
引用
收藏
页码:36 / 45
页数:10
相关论文
共 50 条
  • [1] TILs in ER+/HER2-breast cancer
    Criscitiello, C.
    Vingiani, A.
    Maisonneuve, P.
    Viale, G.
    Viale, G.
    Curigliano, G.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 : 3 - 3
  • [2] Estetrol for treatment of advanced ER+/HER2-breast cancer
    Schmidt, Marcus
    Hoenig, Arnd
    Zimmerman, Yvette
    Verhoeven, Carole
    Almstedt, Katrin
    Battista, Marco
    Lenhard, Hans Georg
    Krijgh, Jan
    Bennink, Herjan Coelingh
    [J]. CANCER RESEARCH, 2020, 80 (04)
  • [3] Tumor infiltrating lymphocytes (TILs) in ER+/HER2-breast cancer
    Criscitiello, C.
    Vingiani, A.
    Maisonneuve, P.
    Viale, G.
    Esposito, A.
    Viale, G.
    Curigliano, G.
    [J]. CANCER RESEARCH, 2019, 79 (04)
  • [4] APOBEC driving genomic evolution in ER+/HER2-breast cancer
    Bos, M.
    Smid, M.
    Sleijfer, S.
    Martens, J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2020, 138 : S105 - S106
  • [5] Tumor-infiltrating lymphocytes (TILs) in ER+/HER2-breast cancer
    Criscitiello, C.
    Vingiani, A.
    Maisonneuve, P.
    Viale, G.
    Vialel, G.
    Curigliano, G.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2020, 183 (02) : 347 - 354
  • [6] ASO Author Reflections: The Changing Role of Gene Expression Profiling in ER+/HER2-Breast Cancer
    van Steenhoven, Julia E. C.
    van Dalen, T.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2019, 26 (Suppl 3) : S800 - S801
  • [7] Role of androgen receptor expression in early stage ER+/PgR-/HER2-breast cancer
    Tagliaferri, Barbara
    Quaquarini, Erica
    Palumbo, Raffaella
    Balletti, Emanuela
    Presti, Daniele
    Malovini, Alberto
    Agozzino, Manuela
    Teragni, Cristina Maria
    Terzoni, Andrea
    Bernardo, Antonio
    Villani, Laura
    Sottotetti, Federico
    [J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
  • [8] Targeting of endocrine therapy-induced estrogen-receptor/HER2-cross-talk in circulating tumor cells from metastatic ER+/HER2-breast cancer: Implications for treatment of ER+/HER2-breast cancer
    Thaler, S.
    Rosswag, S.
    Pantel, K.
    Sleeman, J. P.
    Schmidt, M.
    Cotarelo, C. L.
    [J]. CANCER RESEARCH, 2019, 79 (04)
  • [9] Integrated proteomic and informatic assessment of ER+/HER2-and ER-/HER2-breast tumors
    Wang, Guisong
    Shah, Punit
    Tolstikov, Vladimir
    Raj-Kumar, Praveen-Kumar
    Liu, Jianfang
    Sturtz, Lori A.
    Fantacone-Campbell, J. Leigh
    Zingmark, Rebecca
    Hooke, Jeffrey A.
    Cutler, Mary L.
    Richardson, Kris
    Rodrigues, Leonardo
    Bussberg, Valerie
    Sarangarajan, Rangaprasad
    Narain, Niven R.
    Hu, Hai
    Kiebish, Michael A.
    Kovatich, Albert J.
    Shriver, Craig D.
    [J]. CANCER RESEARCH, 2020, 80 (16)
  • [10] Is 18FDG uptake useful to decide on chemotherapy in ER+/HER2-breast cancer?
    Groheux, David
    Hindie, Elif
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 (09) : 1571 - 1573